{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:26:50Z","timestamp":1789759610661,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41409-019-0584-3","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T18:10:53Z","timestamp":1559585453000},"page":"325-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?"],"prefix":"10.1038","volume":"55","author":[{"given":"Nour M.","family":"Moukalled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"584_CR1","unstructured":"D\u2019Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. \nhttp:\/\/www.cibmtr.org\n\n. 2018."},{"key":"584_CR2","doi-asserted-by":"publisher","unstructured":"Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transpl. 2019. \nhttps:\/\/doi.org\/10.1038\/s41409-019-0465-9\n\n.","DOI":"10.1038\/s41409-019-0465-9"},{"key":"584_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/bmt.2014.133","volume":"49","author":"MA Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socie G, et al. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2014;49:1170\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599\u2013606.","journal-title":"Blood"},{"key":"584_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"584_CR6","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1182\/blood.V89.11.4226","volume":"89","author":"J Sierra","year":"1997","unstructured":"Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226\u201335.","journal-title":"Blood"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/joim.12720","volume":"283","author":"C Craddock","year":"2018","unstructured":"Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, et al. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med. 2018;283:371\u20139.","journal-title":"J Intern Med"},{"key":"584_CR8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","volume":"54","author":"R Devillier","year":"2013","unstructured":"Devillier R, Crocchiolo R, Etienne A, Prebet T, Charbonnier A, Furst S, et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma. 2013;54:1228\u201334.","journal-title":"Leuk Lymphoma"},{"key":"584_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.bmt.1705852","volume":"40","author":"DA Pollyea","year":"2007","unstructured":"Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2007;40:1027\u201332.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","volume":"19","author":"G Thanarajasingam","year":"2013","unstructured":"Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1713\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"584_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bmt.2009.266","volume":"45","author":"A Czibere","year":"2010","unstructured":"Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transpl. 2010;45:872\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR12","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938\u201345.","journal-title":"J Clin Oncol"},{"key":"584_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1046\/j.1365-2141.2001.03150.x","volume":"115","author":"R Pawson","year":"2001","unstructured":"Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG+\/\u2212 Ida) and second allogeneic stem cell transplant. Br J Haematol. 2001;115:622\u20139.","journal-title":"Br J Haematol"},{"key":"584_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/bmt.2012.267","volume":"48","author":"P Christopoulos","year":"2013","unstructured":"Christopoulos P, Schmoor C, Waterhouse M, Marks R, Wasch R, Bertz H, et al. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transpl. 2013;48:901\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","volume":"22","author":"G Orti","year":"2016","unstructured":"Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico. Biol Blood Marrow Transpl. 2016;22:584\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"584_CR16","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00277-018-3454-y","volume":"97","author":"C Schneidawind","year":"2018","unstructured":"Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol. 2018;97:2491\u2013500.","journal-title":"Ann Hematol"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.13015","volume":"100","author":"HA Aljasem","year":"2018","unstructured":"Aljasem HA, Messner HA, Lipton JH, Kim DDH, Viswabandya A, Thyagu S, et al. Outcome following second allogeneic hematopoietic cell transplantation: a single-center experience. Eur J Haematol. 2018;100:308\u201314.","journal-title":"Eur J Haematol"},{"key":"584_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","volume":"108","author":"M Michallet","year":"2000","unstructured":"Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol. 2000;108:400\u20137.","journal-title":"Br J Haematol"},{"key":"584_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transpl. 2004;34:721\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2008.255","volume":"42","author":"BE Shaw","year":"2008","unstructured":"Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transpl. 2008;42:783\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/bmt.2015.186","volume":"50","author":"T Ruutu","year":"2015","unstructured":"Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transpl. 2015;50:1542\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21:454\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"584_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245\u201353.","journal-title":"JAMA Oncol"},{"key":"584_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.bmt.1705011","volume":"36","author":"C Hosing","year":"2005","unstructured":"Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transpl. 2005;36:157\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","volume":"21","author":"CN Duncan","year":"2015","unstructured":"Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transpl. 2015;21:151\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"584_CR26","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","volume":"19","author":"A Bosi","year":"2001","unstructured":"Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19:3675\u201384.","journal-title":"J Clin Oncol"},{"key":"584_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2013.04.022","volume":"19","author":"JM Foran","year":"2013","unstructured":"Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Perez WS, Bolwell BJ, et al. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. Biol Blood Marrow Transpl. 2013;19:1102\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"584_CR28","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259\u201371.","journal-title":"J Clin Oncol"},{"key":"584_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389.","journal-title":"N Engl J Med"},{"key":"584_CR30","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"584_CR31","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911\u20138.","journal-title":"Leukemia"},{"key":"584_CR32","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","volume":"96","author":"M Mizuki","year":"2000","unstructured":"Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907\u201314.","journal-title":"Blood"},{"key":"584_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"584_CR34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058\u201366.","journal-title":"N Engl J Med"},{"key":"584_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225\u201334.","journal-title":"Cancer Cell"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0584-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:55Z","timestamp":1684617295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0584-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.A.K-D. is a consultant for Daiichi Sankyo. N.M.M. declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}